鲁索替尼乳膏治疗特应性皮炎的效果好吗？

Ruxolitinib cream has a relatively good effect in treating atopic dermatitis. It can reduce skin lesions, relieve dry skin, eczema-like rashes, severe itching and other uncomfortable symptoms, and can also reduce the chance of recurrence. It is one of the better choices for the treatment of atopic dermatitis.

ruxolitinib cream

It is a topical Janus kinase (JAK) inhibitor currently approved for the topical short-term and discontinuous chronic treatment of patients 12 years and older with mild to moderate atopic dermatitis. It is also approved for the treatment of non-segmental vitiligo in adults and children 12 years and older.

Ruxolitinib cream for the treatment of atopic dermatitis

In two identical double-blind, randomized, vehicle-controlled trials, TRuE-AD1 and TRuE-AD2, a total of 1249 patients aged 12 years and above were included. The average affected BSA of the subjects was 9.8%, 39% of the subjects had facial involvement areas, 25% of the subjects had an IGA score of 2, and 75% had a score of 3. Baseline itch intensity rating scale was defined as the 7-day average of the worst itch intensity level over the past 24 hours.

In both trials, subjects were randomized in a 2:2:1 ratio to receive ruxolitinib cream or vehicle cream twice daily (BID) for 8 weeks.

The primary efficacy endpoint was the proportion of subjects achieving IGA treatment success (IGA-TS) at week 8, defined as a score of 0 (clear) or 1 (almost clear) and an improvement of ≥2 grades from baseline. Efficacy was also assessed using an improvement of ≥4 points on the pruritus NRS.

After 8 weeks of treatment, the results showed that in the TRuE-AD1 study, the improvement in pruritus NRS was 52.2% in the ruxolitinib cream group and only 15.4% in the placebo group. The IGA score in the ruxolitinib cream group was 53.8% and only 15.1% in the placebo group.

In the TRuE-AD2 study, the improvement in pruritus NRS was 51.3% in the ruxolitinib cream group and only 7.6% in the placebo group. The IGA score in the ruxolitinib cream group was 50.7% and only 16.3% in the placebo group.

Effect of ruxolitinib cream in the treatment of non-segmental vitiligo

The safety and effectiveness of ruxolitinib cream were demonstrated in two clinical trials, NCT04052425 and NCT04057573. In both trials, participants with non-segmental vitiligo were randomly assigned to receive ruxolitinib cream or placebo cream for 24 weeks, after which all patients received an additional 28 weeks of ruxolitinib cream.

At the end of the 24-week treatment period, 30% of patients with ruxolitinib cream experienced at least a 75% improvement in the Facial Vitiligo Area Score Index, compared with 10% of patients in the placebo group.

After using ruxolitinib cream

1. In atopic dermatitis: The most common adverse reactions (≥1%) are nasopharyngitis, diarrhea, bronchitis, ear infection, increased eosinophil count, urticaria, folliculitis, tonsillitis and rhinorrhea.

2. In non-segmental vitiligo: the most common adverse reactions (incidence ≥1%) are acne and itching at the medication site, nasopharyngitis, headache, urinary tract infection, erythema and fever at the medication site, etc.

Recommended related articles: